What's Happening?
Boomerang Medical, a bioelectronic medicine company, has announced a $20 million Series B financing round co-led by Arboretum Ventures and Hatteras Venture Partners. The funds will support the BOOM-IBD2 trial, which is the first pivotal trial of implantable neuromodulation in inflammatory bowel disease, focusing on ulcerative colitis. The trial is enrolling patients at leading medical centers across the U.S. Boomerang Medical aims to evaluate whether sacral neuromodulation can reduce symptom burden and improve quality of life for ulcerative colitis patients.
Why It's Important?
Ulcerative colitis is a chronic autoimmune disease affecting millions, with limited device-based treatment options. Boomerang Medical's trial represents a novel approach to addressing the debilitating symptoms of this condition. The financing will enable the company to complete the trial and potentially offer a new therapy for patients. The recognition by the Crohn's & Colitis Foundation as an 'Emerging Leader in IBD' underscores the significance of Boomerang's work in the field.
What's Next?
Boomerang Medical will continue enrolling patients for the BOOM-IBD2 trial and focus on demonstrating the efficacy of sacral neuromodulation in reducing symptoms of ulcerative colitis. The company aims to move this promising therapy forward, potentially providing a new treatment option for patients and their physicians. Continued support from investors will be crucial in advancing the trial and achieving successful outcomes.
